Skip to main content
. 2017 Apr 28;8(28):46436–46448. doi: 10.18632/oncotarget.17502

Figure 3. Standard mean differences (SMD) for the level of eGFR for patients with versus without cellular/fibrocellular crescents.

Figure 3

The IgAN patients with crescents had decreased eGFR levels (SMD, -0.21; 95% CI, -0.40--0.03; P = 0.023), with high heterogeneity (I2 = 78%; P < 0.001).